Opna Bio Secures Orphan Drug Designation for OPN-6602 in Multiple Myeloma Opna Bio, a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oncology therapeutics, has announced that…
AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying treatments and detection tools for amyloid diseases, has…
Tivic Health Secures Global Rights to Phase III TLR5 Agonist from Statera Biopharma Tivic Health Systems, Inc. (Nasdaq: TIVC) has taken a major step toward expanding its therapeutic portfolio by…
Real-World Outcomes Data for ADSTILADRIN® to Be Presented at 2025 ASCO Genitourinary Symposium Ferring Pharmaceuticals recently announced that three abstracts showcasing ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025…
Alto Neuroscience Reports Positive Interim Analysis Outcome for ALTO-300 Phase 2b Trial in Major Depressive Disorder Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on developing precision…
Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug Abcuro, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat autoimmune diseases and cancer by precisely…
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company specializing in novel neuropsychiatric medicines, has announced the publication of groundbreaking research on its Glyph™ platform. The study, published in…
Taiho Oncology Europe Announces Availability of Futibatinib in Italy for the Treatment of Cholangiocarcinoma Taiho Oncology Europe, a subsidiary of Taiho Pharmaceutical Co., Ltd., has officially announced the availability of…
GenSight Biologics Reports Five-Year Efficacy and Safety Results of LUMEVOQ® Gene Therapy from the REFLECT Study GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has successfully closed its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT), which was initially announced on November 26, 2024. The closing of…
Incyte Announces Q4 and Full-Year 2024 Financial Results, Shares 2025 Guidance and R&D Milestones Incyte reported its financial results for the fourth quarter and full year ended December 31, 2024.…
Aurion Biotech, Inc. (Aurion), a company dedicated to restoring vision for millions through transformative regenerative therapies, has announced the appointment of Donald Munoz as Chief Financial Officer (CFO). Munoz will…
